ProShares Ultra NASDAQ Biotechnology
23 hedge funds and large institutions have $3.6M invested in ProShares Ultra NASDAQ Biotechnology in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
21% more funds holding
Funds holding: 19 → 23 (+4)
1.9% more ownership
Funds ownership: 2.53% → 4.43% (+1.9%)
Holders
23
Holding in Top 10
–
Calls
$1.14M
Puts
$204K
Top Buyers
| 1 | +$631K | |
| 2 | +$561K | |
| 3 | +$237K | |
| 4 |
ATPW
Ashton Thomas Private Wealth
Scottsdale,
Arizona
|
+$30.9K |
| 5 |
DWP
Destiny Wealth Partners
Tavares,
Florida
|
+$22.4K |
Top Sellers
| 1 | -$64K | |
| 2 | -$16.3K | |
| 3 | -$4.97K | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$249 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$83 |
